title: Clinical correlates of anhedonia in patients with Parkinson's disease.
abstract: OBJECTIVE
  To investigate the prevalence and clinical correlates of anhedonia in patients with Parkinson's disease (PD) and to also examine the relationship between anhedonia and the QOL.
  
  
  METHODS
  One hundred and seventeen patients with PD completed the Snaith-Hamilton Pleasure Scale (SHAPS), the State-Trait Anxiety Inventory (STAI), the Beck Depression Inventory Second Edition (BDI-II), Starkstein's Apathy Scale (AS) and a quality of life (QOL) battery. Hoehn and Yahr (HY) staging, the Unified Parkinson's Disease Rating Scale (UPDRS) and the Mini-Mental State Examination (MMSE) were administered on the same day.
  
  
  RESULTS
  Anhedonia (SHAPS score≥3) was diagnosed in 15% of the patients. The SHAPS score was found to be significantly correlated with the HY stage and the UPDRS (I, IVB, IVC, total), BDI-II, AS and STAI (State, Trait) scores. A multivariate analysis revealed that the BDI-II and STAI (Trait) scores significantly influenced the SHAPS scores. The SHAPS scores were found to be negatively correlated with the QOL.
  
  
  CONCLUSIONS
  These findings indicate that anhedonia is associated with depression and anxiety. In addition, recognizing anhedonia in patients with PD is important since it may have a negative effect on the QOL.
authors.affiliation: Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
authors.forename: Kiyohiro
authors.initials: K
authors.lastname: Matsui
authors.forename: Hisao
authors.initials: H
authors.lastname: Tachibana
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Yamanishi
authors.forename: Miyako
authors.initials: M
authors.lastname: Oguru
authors.forename: Kazuo
authors.initials: K
authors.lastname: Toda
authors.forename: Bungo
authors.initials: B
authors.lastname: Okuda
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Oka
mesh_terms: D000368:Aged; D059445:Anhedonia / Q000502:physiology*; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D001007:Anxiety / Q000150:complications / Q000523:psychology; D003863:Depression / Q000209:etiology / Q000523:psychology; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000188:drug therapy / Q000523:psychology*; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa
keywords: Anhedonia; Anxiety; Depression; Parkinson's disease; QOL